Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer
Abstract
BRCA1/2 mutation carriers with breast cancer are at high risk of contralateral disease. Such women often elect to have contralateral risk-reducing mastectomy (CRRM) to reduce the likelihood of recurrence. This study considers whether CRRM improves overall survival. 105 female BRCA1/2 mutation carriers with unilateral breast cancer who underwent CRRM were compared to controls (593 mutation carriers and 105 specifically matched) not undergoing CRRM and diagnosed between 1985 and 2010. Survival was assessed by proportional hazards models, and extended to a matched analysis using stratification by risk-reducing bilateral salpingo-oophorectomy (RRBSO), gene, grade and stage. Median time to CRRM was 1.1 years after the primary diagnosis (range 0.0-13.3). Median follow-up was 9.7 years in the CRRM group and 8.6 in the non-CRRM group. The 10-year overall survival was 89 % in women electing for CRRM (n = 105) compared to 71 % in the non-CRRM group (n = 593); p < 0.001. The survival advantage remained after matching for oophorectomy, gene, grade and stage: HR 0.37 (0.17-0.80, p = 0.008)-CRRM appeared to act independently of RRBSO. CRRM appears to confer a survival advantage. If this finding is confirmed in a larger series it should form part of the counselling procedure at diagnosis of the primary tumour. The indication for CRRM in women who have had RRBSO also requires further research.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
Contralateral Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., Froster, U. G., Schlehe, B., Bechtold, A., Arnold, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9430 · Cited by 314 · see citing works
High constant incidence in twins and other relatives of women with breast cancer
Peto, J., & Mack, T. M. (2000) · Nature Genetics · doi:10.1038/82533 · Cited by 311 · see citing works
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307 · see citing works
van Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R. M., van Asperen, C. J., Rutgers, E. J. T., Veer, L. J. V., & Tollenaar, R. A. �. �. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602703 · Cited by 291 · see citing works
McDonnell, S. K., Schaid, D. J., Myers, J. L., Grant, C. S., Donohue, J. H., Woods, J. E., Frost, M. H., Johnson, J. L., Sitta, D. L., Slezak, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3938 · Cited by 264 · see citing works
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M. B., Kim‐Sing, C., Olsson, H. L., Ainsworth, P., Eisen, A. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21536 · Cited by 253 · see citing works
Yao, K. A., Stewart, A. K., Winchester, D. J., & Winchester, D. P. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1091-3 · Cited by 241 · see citing works
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.120 · Cited by 232 · see citing works
Bedrosian, I., Hu, C., & Chang, G. J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq018 · Cited by 217 · see citing works
Peralta, E. A., Ellenhorn, J. D. I., Wagman, L. D., et al. (2000) · The American Journal of Surgery · doi:10.1016/s0002-9610(00)00505-5 · Cited by 199 · see citing works
Malone, K. E., Begg, C. B., Haile, R. W., Borg, A., Concannon, P., Tellhed, L., Xue, S., Teraoka, S., Bernstein, L., Capanu, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2495 · Cited by 191 · see citing works
Boughey, J. C., Hoskin, T. L., Degnim, A. C., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1136-7 · Cited by 151 · see citing works
Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
Kurian, A. W., McClure, L. A., John, E. M., Horn‐Ross, P. L., Ford, J. M., & Clarke, C. A. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp181 · Cited by 127 · see citing works
Schaapveld, M., Visser, O. J., Louwman, M. W. J., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9709-2 · Cited by 122 · see citing works
Analysis of Matched Cohort Data
Cummings, P., & McKnight, B. (2004) · The Stata Journal Promoting communications on statistics and Stata · doi:10.1177/1536867x0400400305 · Cited by 96 · see citing works
Chung, A. P., Huynh, K. T., Lawrence, C., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2299-1 · Cited by 95 · see citing works
Kaas, R., Verhoef, S., Wesseling, J., Rookus, M., Oldenburg, H., Peeters, M., & Rutgers, E. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181c3c36d · Cited by 92 · see citing works
The Increasing Use of Prophylactic Mastectomy in the Prevention of Breast Cancer
Tuttle, T. M., Abbott, A. M., Arrington, A. K., et al. (2010) · Current Oncology Reports · doi:10.1007/s11912-009-0070-y · Cited by 77 · see citing works
Yi, M., Meric‐Bernstam, F., Middleton, L. P., et al. (2009) · Cancer · doi:10.1002/cncr.24129 · Cited by 64 · see citing works
Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors
Graves, K. D., Peshkin, B. N., Halbert, C. H., DeMarco, T. A., Isaacs, C. J., & Schwartz, M. D. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9423-5 · Cited by 61 · see citing works
Brewster, A. M., Bedrosian, I., Parker, P. A., et al. (2012) · Cancer · doi:10.1002/cncr.27574 · Cited by 58 · see citing works
Vichapat, V., Garmo, H., Holmqvist, M., Liljegren, G., Wärnberg, F., Lambe, M., Fornander, T., Adolfsson, J., Lüchtenborg, M., & Holmberg, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3645 · Cited by 52 · see citing works
Shi, Y.-X., Xia, Q., Peng, R., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1141-7 · Cited by 45 · see citing works
Surgical decisions made by 158 women with hereditary breast cancer aged <50 years
Evans, D. G., Lalloo, F. I., Hopwood, P., Maurice, A., Baildam, A. D., Brain, A., Barr, L. C., & Howell, A. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.05.007 · Cited by 39 · see citing works
Self-citationPrediction of outcome after diagnosis of metachronous contralateral breast cancer
Alkner, S., Bendahl, P., Fernö, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-114 · Cited by 39 · see citing works
Relation of risk of contralateral breast cancer to the interval since the first primary tumour
Rubino, C., Arriagada, R., Delaloge, S., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605434 · Cited by 36 · see citing works
Abdalla, I., Thisted, R. A., & Heimann, R. (2001) · PubMed · Cited by 33 · see citing works
Narod, S. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1479-1 · Cited by 31 · see citing works
Maurice, A., Evans, D. G., Affen, J., Greenhalgh, R., Duffy, S. W., & Howell, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26394 · Cited by 28 · see citing works
Self-citationTilanus‐Linthorst, M. M. A., Bartels, K. C. M., Alves, C., Bakri, B., Crepin, E., van den Ouweland, A., Klijn, J. G. M., Meijers-Heijboer, H. E. J., & Brekelmans, C. T. M. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9054-2 · Cited by 23 · see citing works
Wang, T., Liu, H., Chen, K., et al. (2011) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504011x12935427587966 · Cited by 16 · see citing works
Ciatto, S., Houssami, N., Martinelli, F., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604481 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
van den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104 · see citing works
High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer
Nilsson, M. P., Hartman, L., Kristoffersson, U., Johannsson, O. T., Borg, Å., Henriksson, K., Lanke, E., Olsson, H., & Loman, N. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3115-3 · Cited by 56 · see citing works
- Authors
- Evans, D. G. R., Ingham, S. L., Baildam, A., Ross, G. L., Lalloo, F., Buchan, I., & Howell, A.
- Affiliations
- Wythenshawe Hospital (GB)
- University of Manchester (GB)
- The Christie Hospital (GB)
- Corresponding author
- Evans, D. Gareth R.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2013-06-20
- Volume
- 140
- Issue
- 1
- Pages
- 135-142
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2103700689
- Cited by
- 178
- References
- 32
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 10 · 2023: 9 · 2022: 15 · 2021: 20 · 2020: 19 · 2019: 12 · 2018: 13 · 2017: 14 · 2016: 17 · 2015: 14 · 2014: 15 · 2013: 4 · 2012: 1
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research (RP-PG-0707-10031, NF-SI-0509-10214)
- Manchester Biomedical Research Centre
- Medical Research Council (MR/K006665/1, MC_PC_13042)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- BRCA1 mutation carriers, BRCA2 mutation carriers, hereditary breast cancer, overall survival, contralateral breast cancer, tumor recurrence prevention, genetic counseling
- MeSH terms
- Adult, Breast Neoplasms, Female, Follow-Up Studies, Humans, Mastectomy, Middle Aged, Mutation, Ovariectomy, BRCA1 Protein, BRCA2 Protein, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
